Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
October 28, 2026Pamplona/MadridIn recruitmentEarly phase
CFT7455-2101 Ensayo clínico de fase II, abierto, de un solo grupo, multicéntrico, para evaluar la eficacia de cemsidomida dexametasona en participantes con mieloma múltiple recidivante/refractario. [SP]
En este estudio de investigación, se probará un nuevo producto en investigación llamado cemsidomida junto con dexametasona. La cemsidomida no ha sido aprobada por ninguna autoridad sanitaria, como la Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), la Agencia Europea de Medicamentos (European Medicines Agency, EMA), etc. para el tratamiento de ninguna enfermedad. Sin embargo, las autoridades sanitarias han permitido el uso de cemsidomida en este estudi... -
October 21, 2026Pamplona/MadridIn recruitment
SNDX-5613-0710 Ensayo clínico de fase 3, aleatorizado, doble ciego y controlado con placebo de revumenib en combinación con quimioterapia intensiva en participantes con leucemia mieloide aguda (LMA) de diagnóstico reciente con mutación NPM1. [SP]
El objetivo de este estudio es evaluar si la adición de revumenib a la quimioterapia estándar mejora los resultados en pacientes con leucemia mieloide aguda (LMA) con ciertas mutaciones genéticas, en comparación con la quimioterapia sola. El estudio también evaluará la seguridad de añadir revumenib a la quimioterapia. -
October 20, 2026Pamplona/MadridIn recruitment
BNT323-03 A Phase I/II Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With BNT327 in Participants With Advanced Breast Cancer.
The primary objective is to determine the recommended phase 2 dose (RP2D) of BNT323 in combination with BNT327 by evaluating safety. -
October 20, 2026Pamplona/MadridIn recruitment
D7040C00001 Clinical Performance Study (CPSP) for the Use of the GPC3 (GC33) Clinical Trial Assay to Enroll Patients in AstraZeneca’s Phase I/II Trial of AZD9793 in Adults With Advanced or Metastatic Solid Tumors (RHEA-1).
This study is designed to determine whether the investigational treatment AZD9793, a GPC3-targeting T-cell engager antibody, is safe, tolerable, and has anticancer activity in patients with advanced or metastatic solid tumors that are GPC3-positive. -
October 20, 2026Pamplona/MadridIn recruitment
79635322MMY3004 Randomized Phase 3 Clinical Trial Comparing Ramantamig and Daratumumab Versus Investigator’s Choice of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Patients With Multiple Myeloma.
The main objective of this study is to assess the efficacy of a new treatment, ramantamig-D, compared with the standard treatments DVRd or DRd, in terms of progression-free survival (PFS; the time until a participant’s disease worsens) and the minimal residual disease (MRD)-negative complete response (CR) rate at 12 months (the percentage of participants in whom no cancer cells are detected) in participants with newly diagnosed multiple myeloma (NDMM; an early stage of blood cancer that de... -
October 19, 2026Pamplona/MadridIn recruitment
3082-CL-0301 A Phase III, Double-Blind, Placebo-Controlled, Randomized Clinical Study to Evaluate the Efficacy and Safety of ASP3082 in Combination With mFOLFIRINOX or NALIRIFOX.
The purpose of this study is to determine whether the study drug, ASP3082, is safe and effective as a treatment for people with metastatic pancreatic ductal adenocarcinoma (PDAC) with a KRAS G12D mutation. The study will evaluate ASP3082 in combination with either mFOLFIRINOX (irinotecan, leucovorin [LV] [folinic acid or levofolinate], the fluoropyrimidine 5-fluorouracil [5-FU], and oxaliplatin) OR NALIRIFOX (liposomal irinotecan, LV, 5-FU, and oxaliplatin). The study team will investigate how t... -
September 21, 2026PamplonaIn recruitmentEarly phase
2015-0001 “Clinical trial investigating how well different doses of BI 3822971 are tolerated by people with advanced cancer (solid tumors)”
This study is open to adults with advanced or metastatic solid tumors, such as non-small cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, esophageal squamous cell carcinoma, bladder cancer, vulvar cancer, and cervical cancer. Patients may participate if no standard treatment options are available to them and they have a measurable lesion outside the central nervous system. The aim of this study is to determine how well BI 3822971 is tolerated by people with... -
September 16, 2026PamplonaIn recruitmentEarly phase
68284528MMY2012 Phase 2, multicohort clinical trial to further characterize the efficacy and safety of ciltacabtagene autoleucel
The aim of this study is to gather further information on how cilta-cel works and its safety in the treatment of patients with multiple myeloma, a type of cancer. The study will include different groups of patients, referred to as cohorts. -
September 15, 2026Pamplona/MadridIn recruitment
M26-092 Clinical trial evaluating the safety and efficacy of pivekimab sunirine (PVEK) in combination with venetoclax and azacitidine in adult participants with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy
The aim of this study is to determine the safety and efficacy (how well the study drugs work) of PVEK in combination with venetoclax (VEN) and azacitidine (AZA) in adult patients with newly diagnosed acute myeloid leukemia (AML) who are unable to receive intensive chemotherapy. -
September 15, 2026Pamplona/MadridIn recruitment
CA266-0006 Phase 1/2, open-label, multicenter, randomized clinical trial of pumitamig alone or in combination with ipilimumab in participants with advanced or unresectable hepatocellular carcinoma (HCC) in the first-line setting
This study is designed to help determine whether the study drug pumitamig is effective in treating hepatocellular carcinoma (HCC), a type of liver cancer that is advanced or cannot be removed by surgery (referred to as unresectable).